title: Efficacy of various percutaneous interventions for in-stent restenosis: comprehensive network meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  In-stent restenosis (ISR) remains a difficult problem in interventional cardiology. The relative efficacy and safety of available interventions is not clear. We aimed to perform a network meta-analysis using both direct evidence and indirect evidence to compare all available interventions.
  
  
  RESULTS
  We systematically searched electronic databases for randomized trials comparing ≥2 treatments for ISR. A network meta-analysis was performed using a Bayesian approach. Eleven treatments were compared in 31 studies with 8157 patient-years follow-up. Compared with balloon angioplasty, everolimus-eluting stent (hazard ratio [95% credibility interval], 0.13 [0.048-0.35]), paclitaxel-eluting balloon (0.32 [0.20-0.49]), paclitaxel-eluting cutting balloon (0.054 [0.0017-0.5]), paclitaxel-eluting stent (0.39 [0.24-0.62]), and sirolimus-eluting stent (0.32 [0.18-0.50]) are associated with lower target vessel revascularization. Balloon angioplasty is not different from cutting balloon (0.73 [0.31-1.5]), excimer laser (0.89 [0.29-2.7]), rotational atherectomy (0.96 [0.53-1.7]), and vascular brachytherapy (0.60 [0.35-1.0]). In drug-eluting stent ISR, balloon angioplasty was inferior to everolimus-eluting stent (0.19 [0.049-0.76]), paclitaxel-eluting balloon (0.43 [0.18-0.80]), paclitaxel-eluting stent (0.35 [0.13-0.76]), and sirolimus-eluting stent (0.36 [0.11-0.86]) for target vessel revascularization. There was no difference between treatments in probable or definitive stent thrombosis. The results of binary restenosis and target lesion revascularization were similar. Paclitaxel-eluting cutting balloon, everolimus-eluting stent, and paclitaxel-eluting balloon have the highest probability of being in the top 3 treatments based on low target lesion revascularization, but there was no statistical significant difference between them.
  
  
  CONCLUSIONS
  Balloon angioplasty is inferior to all drug-eluting treatments for ISR, including drug-eluting stent ISR. Drug-eluting stent, particularly everolimus-eluting stent, or paclitaxel-eluting cutting balloon and paclitaxel-eluting balloon should be preferred for treating ISR.
authors.affiliation: From the Department of Cardiology, Chicago Medical School at Rosalind Franklin University of Medicine, North Chicago, IL; and Division of Cardiology, Mount Sinai Hospital Medical Center, Chicago, IL. drankursethi@gmail.com.
authors.forename: Ankur
authors.initials: A
authors.lastname: Sethi
authors.affiliation: From the Department of Cardiology, Chicago Medical School at Rosalind Franklin University of Medicine, North Chicago, IL; and Division of Cardiology, Mount Sinai Hospital Medical Center, Chicago, IL.
authors.forename: Gurveen
authors.initials: G
authors.lastname: Malhotra
authors.affiliation: From the Department of Cardiology, Chicago Medical School at Rosalind Franklin University of Medicine, North Chicago, IL; and Division of Cardiology, Mount Sinai Hospital Medical Center, Chicago, IL.
authors.forename: Sukhchain
authors.initials: S
authors.lastname: Singh
authors.affiliation: From the Department of Cardiology, Chicago Medical School at Rosalind Franklin University of Medicine, North Chicago, IL; and Division of Cardiology, Mount Sinai Hospital Medical Center, Chicago, IL.
authors.forename: Param P
authors.initials: PP
authors.lastname: Singh
authors.affiliation: From the Department of Cardiology, Chicago Medical School at Rosalind Franklin University of Medicine, North Chicago, IL; and Division of Cardiology, Mount Sinai Hospital Medical Center, Chicago, IL.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Khosla
mesh_terms: D000800:Angioplasty, Balloon; D019917:Blood Vessel Prosthesis Implantation; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D054855:Drug-Eluting Stents / Q000706:statistics & numerical data; D000068338:Everolimus / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D062645:Percutaneous Coronary Intervention; D011183:Postoperative Complications; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus
keywords: angioplasty; atherectomy; coronary restenosis; drug-eluting stents; everolimus; paclitaxel; percutaneous coronary intervention